Analysts at BMO Capital upgraded Pfizer Inc. PFE from Market Perform to Outperform.
The price target for Pfizer has been raised from $33 to $36.
Pfizer shares have gained 5.40% over the past 52 weeks, while the S&P 500 index has surged 14.57% in the same period.
Pfizer's shares fell 0.21% to $33.10 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in